Nov 3, 2025
Bespoke’s Conference Call Recaps use AI to summarize lengthy earnings calls. The commentary below is AI-generated and then edited by Bespoke for quality control. As always, none of these summaries should be construed as recommendations to buy or sell any securities, and investors should do their own research and/or consult with a financial professional before making any investment decisions.
Our latest recap available to Bespoke subscribers covers Meta’s (META) Q3 2025 earnings call.
Meta Platforms (META), the owner of social media platforms like Facebook, Instagram, WhatsApp, and Messenger, connects more than 3 billion people daily. The company generates nearly all its revenue from advertising through AI systems that personalize content and optimize ad performance across its apps. Beyond social media, Meta is aggressively investing in AI infrastructure and hardware, developing frontier models, wearable devices like Ray-Ban Meta glasses, and long-term AR/VR projects such as Quest and Orion. Meta’s quarter highlighted record engagement and expanding AI capabilities. Time spent on Facebook rose 5%, Threads 10%, and Instagram video viewing jumped 30%, while Reels hit a $50 billion annual run rate. Advertising performance improved as Advantage+ automation and Lattice models drove higher conversions and lower costs per lead. Meta also expanded its business AIs in Mexico and the Philippines and reported 60% YoY growth in click-to-WhatsApp ads. Hardware demand surged as the new Ray-Ban and Oakley Meta glasses sold out within 48 hours. Management emphasized front-loading compute capacity for superintelligence development and flagged regulatory risks in the EU and US as potential near-term headwinds. The stock fell 11.3% on 10/30 despite EPS and revenue beats as huge AI investments weighed on the stock…
Continue reading our Conference Call Recap for META by becoming a Bespoke Institutional subscriber. You can sign up for Bespoke Institutional now and receive a 14-day trial to read our newest Conference Call Recap. To sign up, choose either the monthly or annual checkout link below:
Bespoke Institutional – Monthly Payment Plan
Bespoke Institutional – Annual Payment Plan
Oct 31, 2025
Bespoke’s Conference Call Recaps use AI to summarize lengthy earnings calls. The commentary below is AI-generated and then edited by Bespoke for quality control. As always, none of these summaries should be construed as recommendations to buy or sell any securities, and investors should do their own research and/or consult with a financial professional before making any investment decisions.
Our latest recap available to Bespoke subscribers covers Visa’s (V) Q4 2025 earnings call.
Visa (V) operates the world’s largest electronic payments network, connecting more than 4 billion cards, bank accounts, and digital wallets through roughly 12 billion endpoints. The company doesn’t issue cards or extend credit but provides the infrastructure that enables global commerce, handling $14 trillion in payments volume in fiscal 2025. Visa’s fiscal Q4 results showed steady consumer resilience despite global uncertainty. Payments volume rose 9% YoY, cross-border transactions climbed 11%, and value-added services revenue jumped 25%. Management emphasized growth in agentic commerce (AI-powered shopping experiences) and accelerating use of stablecoins for settlement and cross-border money movement. Tokenized transactions now exceed 16 billion, and Visa is enabling banks to mint and burn stablecoins. Tap-to-pay reached 79% of global face-to-face transactions, while Visa Direct volumes surged 27%. CEO Ryan McInerney called Visa a “hyperscaler” for the payments ecosystem, integrating AI across all operations heading into a year boosted by the Olympics and FIFA World Cup. Shares fell 1.8% on 10/29 despite EPS and revenue beats…
Continue reading our Conference Call Recap for V by becoming a Bespoke Institutional subscriber. You can sign up for Bespoke Institutional now and receive a 14-day trial to read our newest Conference Call Recap. To sign up, choose either the monthly or annual checkout link below:
Bespoke Institutional – Monthly Payment Plan
Bespoke Institutional – Annual Payment Plan
Oct 31, 2025
Bespoke’s Conference Call Recaps use AI to summarize lengthy earnings calls. The commentary below is AI-generated and then edited by Bespoke for quality control. As always, none of these summaries should be construed as recommendations to buy or sell any securities, and investors should do their own research and/or consult with a financial professional before making any investment decisions.
Our latest recap available to Bespoke subscribers covers Caterpillar’s (CAT) Q3 2025 earnings call.
Caterpillar (CAT) is the world’s largest manufacturer of heavy equipment used in construction, mining, energy, and transportation. Its signature yellow machines (excavators, dozers, trucks, and engines) are sold through a global dealer network that serves infrastructure builders, miners, energy producers, and industrial operators. Beyond machines, Caterpillar’s engine and power systems businesses, including Solar Turbines. Caterpillar reported a record backlog of $39.8 billion, fueled by surging demand for data-center prime power and oil and gas engines. Management highlighted data center expansion tied to AI as a major driver for power generation orders, with long lead times now emerging for large turbines. Tariff headwinds reached the top end of estimates ($500–$600 million) but were partly offset by stronger E&T (Energy & Transportation) margins. North American construction remained firm on IIJA (Infrastructure Investment and Jobs Act) projects, while Asia-Pacific softened outside China. Resource Industries saw continued capital discipline despite healthy mining truck orders and rising adoption of autonomy. On better-than-expected results, CAT shares rose 11.6% on 10/29…
Continue reading our Conference Call Recap for CAT by becoming a Bespoke Institutional subscriber. You can sign up for Bespoke Institutional now and receive a 14-day trial to read our newest Conference Call Recap. To sign up, choose either the monthly or annual checkout link below:
Bespoke Institutional – Monthly Payment Plan
Bespoke Institutional – Annual Payment Plan
Oct 31, 2025
An earnings triple play is a stock that reports earnings and manages to 1) beat analyst EPS estimates, 2) beat analyst sales estimates, and 3) raise forward guidance. You can read more about “triple plays” at Investopedia.com where they’ve given Bespoke credit for popularizing the term. We like triple plays as an indication that a company’s business is firing on all cylinders, with better-than-expected results and an improving outlook. A triple play is indicative of positive “fundamental momentum” instead of pure fundamentals, and there are always plenty of names with both high and low valuations on our quarterly list.
Bespoke’s Triple Play Report highlights companies that have recently reported earnings triple plays, and it features commentary from management on triple-play conference calls, company descriptions and analysis, and price charts. Bespoke’s Triple Play Report is available at the Bespoke Institutional level only. You can sign up for Bespoke Institutional now and receive a 14-day trial to read this week’s Triple Play Report, which features 20 new stocks. To sign up, choose either the monthly or annual checkout link below:
Bespoke Institutional – Monthly Payment Plan
Bespoke Institutional – Annual Payment Plan
Medpace (MEDP) is an example of a company that recently reported an earnings triple play after the close on 10/22. MEDP reported its second straight triple play, and the stock was up 9.1% on 10/23. After the previous quarter’s triple play report, the stock skyrocketed 54.7%! It hit another all-time high after its latest triple play and is up 74.7% YTD.
Here’s how AI describes the company: Medpace (MEDP) is a global clinical research company that helps biotech and pharmaceutical firms bring new drugs to market by managing every stage of the clinical trial process. The company handles trial design, patient recruitment, site coordination, data analysis, and regulatory submissions under one roof, which gives it tight control over quality and timing. Its work spans a range of therapeutic areas but has become especially concentrated in metabolic disease, oncology, and cardiovascular trials, with a growing portion of business tied to obesity and GLP-1 drug development. A large part of its future revenue comes from its “backlog” of awarded projects that have yet to start, giving strong visibility into client demand.
Medpace’s quarter showed how it is benefiting from the surge in obesity and metabolic disease drug development, which has become one of the hottest areas in biotech. Revenue climbed 23.7% to $659.9 million as the company managed a growing volume of late-stage GLP-1 studies, which are larger, faster-paced, and more expensive to run because of high site and investigator costs. After several quarters of disruption from study cancellations, management said the environment has improved sharply, with fewer cancellations and more consistent client funding. That allowed the value of awarded but not-yet-launched projects to grow 30% from last year, positioning the company for continued growth as those trials move into active enrollment. Hiring was strongest in the US, where most GLP-1 trials are based, and India remains a key location for back-office and data work as Medpace scales up to meet record demand.
Looking at the snapshot below from our Earnings Explorer, Medpace (MEDP) has started to find its footing again after hitting somewhat of a rough stretch in 2024, headlined by revenue misses and heavy declines for the stock after reporting. In the last year, though, MEDP has been consistent with EPS and revenue beats, and with two recent triple plays, investors are coming back around to the stock. Historically speaking, MEDP has been a reliable earnings bet against estimates, with EPS and revenue beat rates going back to 2016 of 89% and 78%, respectively, which are both meaningfully above average.
You can read more about MEDP and the 21 other triple plays we covered in our newest report by starting a Bespoke Institutional trial today.
Bespoke Investment Group, LLC believes all information contained in these reports to be accurate, but we do not guarantee its accuracy. None of the information in these reports or any opinions expressed constitutes a solicitation of the purchase or sale of any securities or commodities. This is not personalized advice. Investors should do their own research and/or work with an investment professional when making portfolio decisions. As always, past performance of any investment is not a guarantee of future results. Bespoke representatives or clients may have positions in securities discussed or mentioned in its published content.
Oct 24, 2025
Bespoke’s Conference Call Recaps use AI to summarize lengthy earnings calls. The commentary below is AI-generated and then edited by Bespoke for quality control. As always, none of these summaries should be construed as recommendations to buy or sell any securities, and investors should do their own research and/or consult with a financial professional before making any investment decisions.
Our latest recap available to Bespoke subscribers covers Procter & Gamble’s (PG) Q1 2026 earnings call.
Procter & Gamble (P&G) is one of the world’s largest consumer goods companies, producing household staples across ten core categories like Fabric Care, Baby Care, Grooming, Oral Care, and Skin & Personal Care. Its iconic brands (Tide, Pampers, Gillette, Olay, and Crest) are used by billions globally and dominate supermarket shelves in over 180 countries. P&G gives investors a read on consumer confidence, pricing power, and retail spending trends across income levels and regions. P&G’s Q1 FY26 call reflected steady results amid a soft global consumption backdrop. Organic sales rose 2% with flat volumes and modest pricing gains, marking the 40th straight quarter of growth. Management highlighted competitive pressure in Fabric and Baby Care, especially in the US and Europe, but pointed to innovations like Tide’s biggest upgrade in 20 years and premium Olay launches in China as key demand drivers. China sales rose 5% while Latin America surged 7%. The company also discussed its restructuring, including cutting up to 7,000 non-manufacturing roles and a $1.5B cost-savings target through “Supply Chain 3.0.” Tariffs remain a $500M headwind, but guidance for 0–4% organic growth was reaffirmed. On better-than-expected results, PG shares were up 3% at the open on 10/24…
Continue reading our Conference Call Recap for PG by becoming a Bespoke Institutional subscriber. You can sign up for Bespoke Institutional now and receive a 14-day trial to read our newest Conference Call Recap. To sign up, choose either the monthly or annual checkout link below:
Bespoke Institutional – Monthly Payment Plan
Bespoke Institutional – Annual Payment Plan
Oct 24, 2025
Bespoke’s Conference Call Recaps use AI to summarize lengthy earnings calls. The commentary below is AI-generated and then edited by Bespoke for quality control. As always, none of these summaries should be construed as recommendations to buy or sell any securities, and investors should do their own research and/or consult with a financial professional before making any investment decisions.
Our latest recap available to Bespoke subscribers covers Intuitive Surgical’s (ISRG) Q3 2025 earnings call.
Intuitive Surgical (ISRG) develops and manufactures robotic-assisted surgical systems, most notably the da Vinci and Ion platforms. These systems combine robotics, advanced imaging, and AI to help surgeons perform minimally invasive procedures with greater precision and consistency. The company serves hospitals and healthcare networks globally, with applications spanning general surgery, urology, gynecology, thoracic, and lung biopsy procedures. ISRG’s innovation pipeline, such as its Single-Port (SP) system, force-feedback instrumentation, and AI-powered navigation, makes it a leading barometer for how technology and automation are transforming operating rooms worldwide. ISRG reported another strong quarter as worldwide procedures rose 20% and revenue climbed 23% to $2.5 billion. Adoption of the da Vinci 5 system accelerated, with 240 of 427 placements coming from the newest model. The Ion platform grew 52% in procedures, aided by new FDA-cleared AI imaging features that improved precision in lung diagnostics. SP procedures surged 91%, reflecting early success in new indications. While bariatric volumes softened amid GLP-1 drug use, benign general surgery remained robust. Internationally, growth was broad but tempered by budget pressure in Japan and China. Management highlighted AI integration, digital case insights, and refurbished systems as long-term growth drivers. On better-than-expected results, ISRG rallied 19% after-hours on 10/21…
Continue reading our Conference Call Recap for ISRG by becoming a Bespoke Institutional subscriber. You can sign up for Bespoke Institutional now and receive a 14-day trial to read our newest Conference Call Recap. To sign up, choose either the monthly or annual checkout link below:
Bespoke Institutional – Monthly Payment Plan
Bespoke Institutional – Annual Payment Plan
